PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
Targeting the androgen receptor in breast cancer
The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy
Purpose: The major obstacle in the management of advanced prostate cancer is the
occurrence of resistance to endocrine therapy. Although the androgen receptor (AR) has …
occurrence of resistance to endocrine therapy. Although the androgen receptor (AR) has …
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
H Neuwirt, J Bouchal, G Kharaishvili, C Ploner… - Cell Communication and …, 2020 - Springer
Background Androgen receptor targeted therapies have emerged as an effective tool to
manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy …
manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy …
Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts
Despite significant therapeutic advances in recent years, treatment of metastatic prostate
cancer (PCa) remains palliative, owing to the inevitable occurrence of drug resistance …
cancer (PCa) remains palliative, owing to the inevitable occurrence of drug resistance …
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
F Handle, S Prekovic, C Helsen, T Van den Broeck… - Scientific reports, 2019 - nature.com
Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard
treatment for metastatic castration resistant prostate cancer (mCRPC), but it inevitably leads …
treatment for metastatic castration resistant prostate cancer (mCRPC), but it inevitably leads …
Androgen deprivation induces reprogramming of prostate cancer cells to stem-like cells
BG Sánchez, A Bort, D Vara-Ciruelos, I Díaz-Laviada - Cells, 2020 - mdpi.com
In the past few years, cell plasticity has emerged as a mode of targeted therapy evasion in
prostate adenocarcinoma. When exposed to anticancer therapies, tumor cells may switch …
prostate adenocarcinoma. When exposed to anticancer therapies, tumor cells may switch …
p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer
The androgen receptor (AR) pathway plays a central role in the development of castration-
resistant prostate cancer (CRPC). The histone demethylase JMJD1A has been shown to …
resistant prostate cancer (CRPC). The histone demethylase JMJD1A has been shown to …
KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells
E Metzger, S Wang, S Urban, D Willmann… - Nature structural & …, 2019 - nature.com
Histone lysine methylation is generally performed by SET domain methyltransferases and
regulates chromatin structure and gene expression. Here, we identify human C21orf127 …
regulates chromatin structure and gene expression. Here, we identify human C21orf127 …